Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Survodutide - Boehringer Ingelheim

Next Previous
Drug Profile

Survodutide - Boehringer Ingelheim

Alternative Names: BI-456906; BI-456909

Latest Information Update: 04 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Boehringer Ingelheim; Zealand Pharma
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
  • Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis; Obesity
  • Phase II Type 2 diabetes mellitus
  • No development reported Liver cirrhosis

Most Recent Events

  • 22 Oct 2025 Boehringer Ingelheim completes a phase I trial for Obesity (In volunteers) (SC, Injection) (NCT06200467)
  • 08 Oct 2025 University Medical Center Groningen plans a phase II ARTIST-CKD trial for Chronic Kidney Disease (Treatment-experienced) in March 2026 (SC, Injection) (NCT07206290)
  • 23 Sep 2025 Boehringer Ingelheim completes a phase I trial in Obesity (Treatment-experienced) in Germany (SC, Injection) (NCT06352411)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top